The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
Status:
Completed
Trial end date:
2019-08-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and efficacy of lucinactant for
inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32 weeks
gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for
Respiratory Distress Syndrome (RDS) compared to neonates receiving nCPAP alone.